Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer
NCT ID: NCT07126626
Last Updated: 2025-08-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
1184 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-08-18
Study Completion Date
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an observational clinical trial, aiming to evaluate the efficacy of the SPOTMAS LUNG (SML) test compared to Low dose CTScan (LDCT)/None contrast CTScan (NCCT) in two distinct risk populations:
* Cohort A: To demonstrate that SML is concordant with LDCT/NCCT in general population lung cancer screening, including low-risk (LRs0-1-2), intermediate-risk (LRs3), and high-risk (LRs4) groups.
* Cohort B: To validate the sensitivity and specificity of SML in the high-risk group (LRs4).
* Cohort A: To demonstrate that SML is concordant with LDCT/NCCT in general population lung cancer screening, including low-risk (LRs0-1-2), intermediate-risk (LRs3), and high-risk (LRs4) groups.
* Cohort B: To validate the sensitivity and specificity of SML in the high-risk group (LRs4).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
NCT03499678
Lung Cancer
Lung Cancer, Nonsmall Cell
Lung Cancer, Small Cell
TERMINATED
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
NCT05337163
Lung Cancer
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
+13 more
COMPLETED
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
NCT04254497
Lung Cancer
COMPLETED
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
NCT05023746
Non-Small Cell Lung Cancer
COMPLETED
Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)
NCT00898209
Lung Cancer
TERMINATED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, multi-center cohort study to access the performance of SPOT-MAS Lung (SML) in two different scenarios: lung cancer screening (Cohort A) and lung cancer diagnosis (Cohort B).
Sample size and accuracy analyses were performed independently for the study objectives within each cohort. The minimum sample size for Cohort A is approximately 526 samples. Participants will be randomly selected from the screening population for this study without prior LDCT classification criteria. The minimum sample size for Cohort B is approximately 658 samples. Participants will be selected from individuals who have undergone LDCT/NCCT with LUNG-RADS 4 results.
Each Cohort A or B requires a 50% proportion of smokers and 50% of never-smokers or light-smokers, 10mL blood sample and LDCT/NCCT are collected.
Cohort A: According to current lung cancer screening and diagnosis guidelines, volunteers will undergo the following imaging methods:
Lung-RADS 3: Recommended to have a repeat LDCT after 6 and 12 months. Lung-RADS 0-1-2: Recommended to have a repeat LDCT after 12 months. Lung-RADS 4: Recommended to have contrast-enhanced computed tomography (CECT). Cohort B: According to current lung cancer screening and diagnosis guidelines, the Lung-RADS 4 group will be recommended for contrast-enhanced computed tomography (CECT).
Cohort A and B:
If CECT results show a lesion ≥8mm in the lung, biopsy is recommended, and histopathological results evaluated.
* If histopathology is malignant/confirms cancer: proceed with treatment. Treatment costs ARE NOT covered by the study.
* If histopathology is benign: repeat LDCT after 12 months. If CECT results show a lesion \<8mm in the lung, or no lesion is seen in the lung, repeat LDCT after 12 months.
LDCT or CECT fee in Month 6 and Month 12 will be covered by this study.
Sample size and accuracy analyses were performed independently for the study objectives within each cohort. The minimum sample size for Cohort A is approximately 526 samples. Participants will be randomly selected from the screening population for this study without prior LDCT classification criteria. The minimum sample size for Cohort B is approximately 658 samples. Participants will be selected from individuals who have undergone LDCT/NCCT with LUNG-RADS 4 results.
Each Cohort A or B requires a 50% proportion of smokers and 50% of never-smokers or light-smokers, 10mL blood sample and LDCT/NCCT are collected.
Cohort A: According to current lung cancer screening and diagnosis guidelines, volunteers will undergo the following imaging methods:
Lung-RADS 3: Recommended to have a repeat LDCT after 6 and 12 months. Lung-RADS 0-1-2: Recommended to have a repeat LDCT after 12 months. Lung-RADS 4: Recommended to have contrast-enhanced computed tomography (CECT). Cohort B: According to current lung cancer screening and diagnosis guidelines, the Lung-RADS 4 group will be recommended for contrast-enhanced computed tomography (CECT).
Cohort A and B:
If CECT results show a lesion ≥8mm in the lung, biopsy is recommended, and histopathological results evaluated.
* If histopathology is malignant/confirms cancer: proceed with treatment. Treatment costs ARE NOT covered by the study.
* If histopathology is benign: repeat LDCT after 12 months. If CECT results show a lesion \<8mm in the lung, or no lesion is seen in the lung, repeat LDCT after 12 months.
LDCT or CECT fee in Month 6 and Month 12 will be covered by this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Lung Diseases
Lung Cancer Screening
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Cohort A
1. Volunteers (participants) aged 50-80 years at the time of consent.
1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.
2. 50% never-smokers or light smokers (\< 20 pack-years or quit \> 15 years) who are first- or second-degree relatives of LC patients.
2. Willing to undergo LDCT/NCCT of the chest for lung cancer screening.
3. Willing to consent to an investigational blood draw during the index LDCT/NCCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis.
4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.
Cohort B
1. Subjects aged 50-80 years at the time of consent.
1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.
2. 50% never-smokers or light smokers (\< 20 pack-years or quit \> 15 years) who are first- or second-degree relatives of LC patients.
2. Have undergone LDCT/NCCT of the chest for lung cancer screening/diagnosis, including only high-risk lesions (LUNG-RADS 4).
3. Willing to consent to an investigational blood draw before any invasive procedures (CECT/PET-CT/biopsy) or treatment for lung cancer diagnosis.
4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.
1. Volunteers (participants) aged 50-80 years at the time of consent.
1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.
2. 50% never-smokers or light smokers (\< 20 pack-years or quit \> 15 years) who are first- or second-degree relatives of LC patients.
2. Willing to undergo LDCT/NCCT of the chest for lung cancer screening.
3. Willing to consent to an investigational blood draw during the index LDCT/NCCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis.
4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.
Cohort B
1. Subjects aged 50-80 years at the time of consent.
1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.
2. 50% never-smokers or light smokers (\< 20 pack-years or quit \> 15 years) who are first- or second-degree relatives of LC patients.
2. Have undergone LDCT/NCCT of the chest for lung cancer screening/diagnosis, including only high-risk lesions (LUNG-RADS 4).
3. Willing to consent to an investigational blood draw before any invasive procedures (CECT/PET-CT/biopsy) or treatment for lung cancer diagnosis.
4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.
Exclusion Criteria
1. Subject has a health problem that substantially limits life expectancy and/or the ability or willingness to have curative lung surgery.
2. Subject is undergoing CECT for investigation of highly suspicious symptoms for lung cancer.
3. Pre-existing or history of lung cancer.
4. History of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study).
5. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
6. Currently receiving treatment for pneumonia.
7. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.
8. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
9. Participation in a clinical research study in which an experimental medication and/or medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening.
\-
\-
2. Subject is undergoing CECT for investigation of highly suspicious symptoms for lung cancer.
3. Pre-existing or history of lung cancer.
4. History of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study).
5. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
6. Currently receiving treatment for pneumonia.
7. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.
8. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
9. Participation in a clinical research study in which an experimental medication and/or medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening.
\-
\-
Minimum Eligible Age
50 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gene Solutions
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Genetics Institute
Ho Chi Minh City, , Vietnam
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Vietnam
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Infante MV, Cardillo G. Lung cancer screening in never-smokers: facts and remaining issues. Eur Respir J. 2020 Nov 12;56(5):2002949. doi: 10.1183/13993003.02949-2020. Print 2020 Nov. No abstract available.
Reference Type
BACKGROUND
Kocher Wulfeck M, Plesner S, Herndon JE 2nd, Christensen JD, Patz EF Jr. Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program. Lung Cancer. 2023 Dec;186:107420. doi: 10.1016/j.lungcan.2023.107420. Epub 2023 Nov 10.
Reference Type
BACKGROUND
Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet. 2002 Feb 2;359(9304):431-4. doi: 10.1016/S0140-6736(02)07605-5.
Reference Type
BACKGROUND
https://doi.org/10.1158/2159-8290.CD-24-0519
Reference Type
BACKGROUND
Hu X, Luo K, Shi H, Yan X, Huang R, Zhao B, Zhang J, Xie D, Zhang W. Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer. Clin Epigenetics. 2022 Jan 24;14(1):15. doi: 10.1186/s13148-022-01233-7.
Reference Type
BACKGROUND
Guo W, Chen X, Liu R, Liang N, Ma Q, Bao H, Xu X, Wu X, Yang S, Shao Y, Tan F, Xue Q, Gao S, He J. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. doi: 10.1016/j.ebiom.2022.104131. Epub 2022 Jun 30.
Reference Type
BACKGROUND
http://dx.doi.org/10.1002/mco2.766
Reference Type
BACKGROUND
Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Janne PA, Mitsudomi T, Goss GD. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Jul;12(7):1061-1070. doi: 10.1016/j.jtho.2017.04.003. Epub 2017 Apr 17.
Reference Type
BACKGROUND
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Ostrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sorensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018 Nov 7;10(466):eaat4921. doi: 10.1126/scitranslmed.aat4921.
Reference Type
BACKGROUND
Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016 Jan 14;164(1-2):57-68. doi: 10.1016/j.cell.2015.11.050.
Reference Type
BACKGROUND
Weiss G, Schlegel A, Kottwitz D, Konig T, Tetzner R. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol. 2017 Jan;12(1):77-84. doi: 10.1016/j.jtho.2016.08.123. Epub 2016 Aug 18.
Reference Type
BACKGROUND
Johnson DA, Barclay RL, Mergener K, Weiss G, Konig T, Beck J, Potter NT. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014 Jun 5;9(6):e98238. doi: 10.1371/journal.pone.0098238. eCollection 2014.
Reference Type
BACKGROUND
Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009 Dec;1(2):239-59. doi: 10.2217/epi.09.33.
Reference Type
BACKGROUND
McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009 Jun 15;15(12):3927-37. doi: 10.1158/1078-0432.CCR-08-2784. Epub 2009 Jun 9.
Reference Type
BACKGROUND
Pecuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.
Reference Type
BACKGROUND
Filipska M, Rosell R. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Mol Oncol. 2021 Jun;15(6):1667-1682. doi: 10.1002/1878-0261.12983. Epub 2021 May 26.
Reference Type
BACKGROUND
Zhao X, Dai F, Mei L, Huang D, Shen X, Zhang H, She X, Ma Z. The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC. Front Oncol. 2021 Jul 16;11:671963. doi: 10.3389/fonc.2021.671963. eCollection 2021.
Reference Type
BACKGROUND
Zhang X, Li J, Lan X, Li J. Cell-free DNA-associated multi-feature applications in cancer diagnosis and treatment. Vol. 4, Clinical and Translational Discovery. 2024.
Reference Type
BACKGROUND
Volckmar AL, Sultmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A, Dietz S. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Genes Chromosomes Cancer. 2018 Mar;57(3):123-139. doi: 10.1002/gcc.22517. Epub 2017 Dec 20.
Reference Type
BACKGROUND
Qi T, Pan M, Shi H, Wang L, Bai Y, Ge Q. Cell-Free DNA Fragmentomics: The Novel Promising Biomarker. Int J Mol Sci. 2023 Jan 12;24(2):1503. doi: 10.3390/ijms24021503.
Reference Type
BACKGROUND
Stoecklein NH, Fischer JC, Niederacher D, Terstappen LW. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 2016;16(2):147-64. doi: 10.1586/14737159.2016.1123095. Epub 2015 Dec 16.
Reference Type
BACKGROUND
Wan S, Kim TH, Smith KJ, Delaney R, Park GS, Guo H, Lin E, Plegue T, Kuo N, Steffes J, Leu C, Simeone DM, Razimulava N, Parikh ND, Nagrath S, Welling TH. New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. Sci Rep. 2019 Dec 9;9(1):18575. doi: 10.1038/s41598-019-54960-y.
Reference Type
BACKGROUND
Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, Karabacak M, Pai V, Yu M, Smith K, Hwang H, Yang J, Shah S, Yarmush R, Sequist LV, Stott SL, Maheswaran S, Haber DA, Kapur R, Toner M. Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Sci Rep. 2017 Sep 7;7(1):10936. doi: 10.1038/s41598-017-11119-x.
Reference Type
BACKGROUND
Alix-Panabieres C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016 May;6(5):479-91. doi: 10.1158/2159-8290.CD-15-1483. Epub 2016 Mar 11.
Reference Type
BACKGROUND
Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, Marinac CR, Chung KC, Lopatin M, Fung ET, Klein EA. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023 Oct 7;402(10409):1251-1260. doi: 10.1016/S0140-6736(23)01700-2.
Reference Type
BACKGROUND
Vacante M, Ciuni R, Basile F, Biondi A. The Liquid Biopsy in the Management of Colorectal Cancer: An Overview. Biomedicines. 2020 Aug 26;8(9):308. doi: 10.3390/biomedicines8090308.
Reference Type
BACKGROUND
Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Inform. 2022 Feb 7;21:11769351221076062. doi: 10.1177/11769351221076062. eCollection 2022.
Reference Type
BACKGROUND
Duy TH, Thọ NV, Linh LTM, Hoàng PM, Tố TT, Thùy BTC, Ngọc NTM, Phương NM. Tỷ lệ và đặc điểm ung thư phổi ở nhóm đối tượng nguy cơ cao đánh giá thông qua chụp cắt lớp vi tính lồng ngực liều thấp. Tạp chí Y học Việt Nam. 2024;537(1).
Reference Type
BACKGROUND
Hà HTN, Tiến ĐD, Khoan LT. Nghiên cứu giá trị của cắt lớp vi tính ngực liều thấp trong phát hiện sớm các nốt mở phổi ác . Tạp Chí Y Dược Huế. 2020;10(4):7-15.
Reference Type
BACKGROUND
Đặng ĐP, Ngô QB, Đinh HV, Nguyễn QĐ. Giá trị của phân loại lung-rads trong chẩn đoán ung thư phổi với nốt mờ đơn độc. Tạp chí Y học Việt Nam. 2022;520(1A).
Reference Type
BACKGROUND
Torres S, Gonzalez A, Cunquero Tomas AJ, Calabuig Farinas S, Ferrero M, Mirda D, Sirera R, Jantus-Lewintre E, Camps C. A profile on cobas(R) EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Rev Mol Diagn. 2020 Jun;20(6):575-582. doi: 10.1080/14737159.2020.1724094. Epub 2020 Feb 20.
Reference Type
BACKGROUND
Winokur RS, Pua BB, Sullivan BW, Madoff DC. Percutaneous lung biopsy: technique, efficacy, and complications. Semin Intervent Radiol. 2013 Jun;30(2):121-7. doi: 10.1055/s-0033-1342952.
Reference Type
BACKGROUND
Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, da Cunha Santos G, Geddie W, Boerner S, Le LW, Keshavjee S. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011 Dec;142(6):1393-400.e1. doi: 10.1016/j.jtcvs.2011.08.037. Epub 2011 Oct 2.
Reference Type
BACKGROUND
Wimaleswaran H, Farmer MW, Irving LB, Jennings BR, Steinfort DP. Pulmonologist-performed transoesophageal sampling for lung cancer staging using an endobronchial ultrasound video-bronchoscope: an Australian experience. Intern Med J. 2017 Feb;47(2):205-210. doi: 10.1111/imj.13330.
Reference Type
BACKGROUND
Cham MD, Henschke CI, Yankelevitz DF. The radiologist's role in pathologic diagnosis of small lung nodules: radiographic methods of tissue acquisition. Current Challenges in Thoracic Surgery. 2022;4.
Reference Type
BACKGROUND
Silvestri GA, Goldman L, Tanner NT, Burleson J, Gould M, Kazerooni EA, Mazzone PJ, Rivera MP, Doria-Rose VP, Rosenthal LS, Simanowith M, Smith RA, Fedewa S. Outcomes From More Than 1 Million People Screened for Lung Cancer With Low-Dose CT Imaging. Chest. 2023 Jul;164(1):241-251. doi: 10.1016/j.chest.2023.02.003. Epub 2023 Feb 10.
Reference Type
BACKGROUND
Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA. 2021 Mar 9;325(10):988-997. doi: 10.1001/jama.2021.1077.
Reference Type
BACKGROUND
Reinke LF, Feemster LC, Backhus LM, Gylys-Colwell I, Au DH. Assessment and Management of Symptoms for Outpatients Newly Diagnosed With Lung Cancer. Am J Hosp Palliat Care. 2016 Mar;33(2):178-83. doi: 10.1177/1049909114557635. Epub 2014 Nov 5.
Reference Type
BACKGROUND
Butler SJ, Louie AV, Sutradhar R, Paszat L, Brooks D, Gershon AS. Impact of chronic obstructive pulmonary disease on lung cancer symptom burden: a population-based study in Ontario, Canada. Transl Lung Cancer Res. 2023 Nov 30;12(11):2260-2274. doi: 10.21037/tlcr-23-560. Epub 2023 Nov 28.
Reference Type
BACKGROUND
Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer incidence in never smokers. J Clin Oncol. 2007 Feb 10;25(5):472-8. doi: 10.1200/JCO.2006.07.2983.
Reference Type
BACKGROUND
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007 Oct;7(10):778-90. doi: 10.1038/nrc2190.
Reference Type
BACKGROUND
Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, McGavic D, Minna JD, Gazdar AF, Schiller J. Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. J Natl Cancer Inst. 2017 Jan 28;109(7):djw295. doi: 10.1093/jnci/djw295. Print 2017 Jan.
Reference Type
BACKGROUND
Zeng Q, Vogtmann E, Jia MM, Parascandola M, Li JB, Wu YL, Feng QF, Zou XN. Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13 years. Thorac Cancer. 2019 Aug;10(8):1717-1724. doi: 10.1111/1759-7714.13141. Epub 2019 Jul 10.
Reference Type
BACKGROUND
Doğan C. Different Characteristics in Lung Cancer Patients Between Age Groups Under 55 and Over 55 Years of Age? South Clin Istanb Eurasia. 2017;
Reference Type
BACKGROUND
Tarigan SP, Soeroso NN, Tumanggor CAK, Gani S, Pradana A. Clinical Profile of Male Patients with Non-Small Cell Lung Cancer in Adam Malik General Hospital, Medan, Indonesia. Open Access Maced J Med Sci. 2019 Aug 29;7(16):2612-2614. doi: 10.3889/oamjms.2019.404. eCollection 2019 Aug 30.
Reference Type
BACKGROUND
Barta JA, Zinner RG, Unger M. Lung Cancer in the Older Patient. Clin Geriatr Med. 2017 Nov;33(4):563-577. doi: 10.1016/j.cger.2017.06.008. Epub 2017 Aug 19.
Reference Type
BACKGROUND
Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19. doi: 10.1007/978-3-319-24223-1_1.
Reference Type
BACKGROUND
Krewski D, Lubin JH, Zielinski JM, Alavanja M, Catalan VS, Field RW, Klotz JB, Letourneau EG, Lynch CF, Lyon JI, Sandler DP, Schoenberg JB, Steck DJ, Stolwijk JA, Weinberg C, Wilcox HB. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology. 2005 Mar;16(2):137-45. doi: 10.1097/01.ede.0000152522.80261.e3.
Reference Type
BACKGROUND
van Loon AJ, Kant IJ, Swaen GM, Goldbohm RA, Kremer AM, van den Brandt PA. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med. 1997 Nov;54(11):817-24. doi: 10.1136/oem.54.11.817.
Reference Type
BACKGROUND
Pope CA 3rd, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 2002 Mar 6;287(9):1132-41. doi: 10.1001/jama.287.9.1132.
Reference Type
BACKGROUND
Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol. 2007 Oct;36(5):1048-59. doi: 10.1093/ije/dym158. Epub 2007 Aug 9.
Reference Type
BACKGROUND
Expert Panel on Thoracic Imaging:; de Groot PM, Chung JH, Ackman JB, Berry MF, Carter BW, Colletti PM, Hobbs SB, McComb BL, Movsas B, Tong BC, Walker CM, Yom SS, Kanne JP. ACR Appropriateness Criteria(R) Noninvasive Clinical Staging of Primary Lung Cancer. J Am Coll Radiol. 2019 May;16(5S):S184-S195. doi: 10.1016/j.jacr.2019.02.008.
Reference Type
BACKGROUND
US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Landefeld CS, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117.
Reference Type
BACKGROUND
Freedman ND, Abnet CC, Caporaso NE, Fraumeni JF Jr, Murphy G, Hartge P, Hollenbeck AR, Park Y, Shiels MS, Silverman DT. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol. 2016 Jun;45(3):846-56. doi: 10.1093/ije/dyv175. Epub 2015 Sep 27.
Reference Type
BACKGROUND
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.
Reference Type
BACKGROUND
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
Reference Type
BACKGROUND
Nguyen VTC, Nguyen TH, Doan NNT, Pham TMQ, Nguyen GTH, Nguyen TD, Tran TTT, Vo DL, Phan TH, Jasmine TX, Nguyen VC, Nguyen HT, Nguyen TV, Nguyen THH, Huynh LAK, Tran TH, Dang QT, Doan TN, Tran AM, Nguyen VH, Nguyen VTA, Ho LMQ, Tran QD, Pham TTT, Ho TD, Nguyen BT, Nguyen TNV, Nguyen TD, Phu DTB, Phan BHH, Vo TL, Nai THT, Tran TT, Truong MH, Tran NC, Le TK, Tran THT, Duong ML, Bach HPT, Kim VV, Pham TA, Tran DH, Le TNA, Pham TVN, Le MT, Vo DH, Tran TMT, Nguyen MN, Van TTV, Nguyen AN, Tran TT, Tran VU, Le MP, Do TT, Phan TV, Nguyen HL, Nguyen DS, Cao VT, Do TT, Truong DK, Tang HS, Giang H, Nguyen HN, Phan MD, Tran LS. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Elife. 2023 Oct 11;12:RP89083. doi: 10.7554/eLife.89083.
Reference Type
BACKGROUND
Wang S, Meng F, Li M, Bao H, Chen X, Zhu M, Liu R, Xu X, Yang S, Wu X, Shao Y, Xu L, Yin R. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer. Am J Respir Crit Care Med. 2023 May 1;207(9):1203-1213. doi: 10.1164/rccm.202109-2019OC.
Reference Type
BACKGROUND
http://dx.doi.org/10.1056/NEJMoa1102873
Reference Type
BACKGROUND
Sagawa M, Sakurada A, Ashizawa K, Maeda S, Nakayama T, Oikado K, Gemba K, Kobayashi T, Torii Y, Takenaka D, Maruyama Y, Mitomo H, Murota M, Yanagawa M, Shibuya K, Sobue T, Harada M, Miura H. Revision of the Lung Cancer Screening Guidelines in 2022. Japanese Journal of Lung Cancer. 2022;62(5).
Reference Type
BACKGROUND
Chinese Expert Group on Early Diagnosis and Treatment of Lung Cancer; China Lung Oncology Group. [China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version)]. Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):1-9. doi: 10.3779/j.issn.1009-3419.2023.102.10. Chinese.
Reference Type
BACKGROUND
Chapter of Respiratory Physicians C of PA of MS. Lung Cancer Screening in Singapore: Professional Guidelines. Singapore; 2025 Jan
Reference Type
BACKGROUND
Lam DC, Liam CK, Andarini S, Park S, Tan DSW, Singh N, Jang SH, Vardhanabhuti V, Ramos AB, Nakayama T, Nhung NV, Ashizawa K, Chang YC, Tscheikuna J, Van CC, Chan WY, Lai YH, Yang PC. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023 Oct;18(10):1303-1322. doi: 10.1016/j.jtho.2023.06.014. Epub 2023 Jun 28.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUNGCARE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of AI-assisted LDCT Screening in Lung Cancer
NCT07280559
NOT_YET_RECRUITING
NA
A Prospective, Observational Trial on the Diagnostic and Prognostic of LM
NCT02607605
UNKNOWN
Benefit of Spectral Information in Patients Suspected for Lung Cancer
NCT06440616
RECRUITING
NA
A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
NCT07322367
NOT_YET_RECRUITING
NA
Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer
NCT07042867
NOT_YET_RECRUITING
NA
Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population
NCT02277366
TERMINATED
Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer
NCT00005071
UNKNOWN
NA
Clinical Evaluation of the Lung Cancer AI-based Decision Support Tool in Low-Dose Lung CT
NCT07052773
COMPLETED
Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
NCT05587114
RECRUITING
Early Stage Lung Cancer Screening With Low-dose Computed Tomographic
NCT02898441
UNKNOWN
NA
DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules
NCT06220305
RECRUITING
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer
NCT04156360
UNKNOWN
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
NCT07331701
NOT_YET_RECRUITING
SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)
NCT05724264
RECRUITING
NA
Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT
NCT07327736
NOT_YET_RECRUITING
NA
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156
COMPLETED
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
NCT02833467
UNKNOWN
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
NCT07057102
RECRUITING
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
NCT03317080
UNKNOWN
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
NCT00471978
RECRUITING
Cancer Panel From Blood of Lung Cancer Patients
NCT03235765
UNKNOWN
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671
ACTIVE_NOT_RECRUITING
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
NCT02715102
TERMINATED
Novel Detection System for Lung Cancer Curative Effect Monitoring
NCT02666755
UNKNOWN